Navigation Links
Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer

CAMBRIDGE, Mass., May 22, 2013 /PRNewswire/ -- Moderna Therapeutics, the pioneering company developing messenger RNA therapeutics™, a revolutionary new treatment modality to enable the in vivo production of therapeutic proteins, announced today that John Reynders will join Moderna in early July as its first Chief Information Officer.

Reynders is a proven leader in the design and implementation of information systems underlying all phases of drug development, from discovery to translation, clinical operations and commercial preparedness. John has also been at the vanguard of the pharmaceutical industry's efforts in big data analytics, cloud-based computing, and innovation networks. He joins Moderna from AstraZeneca, where he served as Vice President of R&D Information, and has held senior leadership positions over the past decade at Johnson & Johnson, Lilly, and Celera Genomics.

"We are building a company capable of driving innovation on a scale and at a pace that were unimaginable until recently, and our information systems must be able to fuel that vision," said Stephane Bancel , founding president and CEO of Moderna. "John has long been on the forefront of the information revolution that is reshaping drug development and healthcare, and he has a strong vision for how we can design an information resource capable of propelling Moderna – and the entire field of messenger RNA therapeutics™ – well into the future."

Reynders will lead a team at Moderna in creating an information infrastructure critical to all aspects of the company's innovation model, including the use of genomic data in drug design; the integration and instant sharing of knowledge from a variety of preclinical and clinical settings; and the seamless interaction of a wide network of collaborators, partners, and potential spinoff companies.

"It is tremendously exciting to be involved in designing the drug company of the future at this critical moment in Moderna's scale up, when knowledge of the potential application of messenger RNA therapeutics™ is exploding," Reynders said. "For Moderna and the entire field to fully capitalize on this profound advance for patients will require a full end-to-end informatics integration of the Moderna pipeline, creating the industry's first fully digital biotech. It will also require all of us to design new ways of working together, not just within the walls of Moderna but with a vast network of collaborators around the world. This is a once in a lifetime opportunity and I am proud to be a part of it."

About Moderna Therapeutics

Moderna is pioneering messenger RNA therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. This breakthrough platform addresses currently undruggable targets and offers a superior alternative to existing drug modalities for a wide range of disease conditions. Moderna has developed a broad intellectual property estate including 120 patent applications with 6,500 claims ranging from novel nucleotide chemistries to specific drug compositions. The company plans to develop and commercialize its innovative mRNA drugs – initially for rare diseases and oncology – while partnering drug candidates in other therapeutic areas in order to rapidly deliver this innovation to patients. Based in Cambridge, Massachusetts, Moderna is privately held and was founded in 2010 by Flagship VentureLabs in association with leading scientists from Harvard University and Massachusetts Institute of Technology. Visit to learn more.

For information contact:
Dan Quinn
Feinstein Kean Healthcare

SOURCE Moderna Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. New Resource Provides Herb Industry With Sources of Quality Specifications
2. Garage Start-ups Now Possible in Life Sciences Industry
3. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
4. Internal and External Communications Excellence for the Pharmaceutical Industry: Increasing Organizational Effectiveness
5. Free Job Training: 55 Grants Available to Retrain Workers for Biofuels Industry
6. Hybrid Fuels, Inc. Appoints Industry Expert as New CEO
7. Prolongs Large Scale Manufacturing of Sickle Cell Product to be Headed by Industry Veteran
8. Ohios Bioscience Industry Effort Paying Off With Increase in Graduates and Accolades for the State
9. Hemodialysis Machine Industry 2012 Global & China Market Research Report - ReportsnReports
10. Live Press Briefing on Findings of Biomedical Industry CEO Survey
11. Life Technologies Plant in Austin, Texas Named One of IndustryWeeks Top Ten Best Plants for 2011
Post Your Comments:
(Date:11/26/2015)... November 26, 2015 --> ... specializing in imaging technologies, announced today that it has received ... of the Horizon 2020 European Union Framework Programme for Research ... clinical trial in breast cancer. , --> ... --> --> The study aims ...
(Date:11/25/2015)... and HOLLISTON, Mass. , Nov. ... (Nasdaq: HART ), a biotechnology company developing bioengineered ... Jim McGorry will present at the LD ... 2015 at 2:30 p.m. PT. The presentation will be ... 30 days. Management will also be available at the ...
(Date:11/25/2015)... Oregon , November 25, 2015 ... Market Research Report is a professional and in-depth ... industry.      (Logo: ) ... overview of the industry including definitions, classifications, applications ... is provided for the international markets including development ...
(Date:11/24/2015)... Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ... New York on Wednesday, December 2 at ... , president and CEO, will provide a corporate overview. ... at 1:00 p.m. ET/10:00 a.m. PT . ... will provide a corporate overview. --> th Annual ...
Breaking Biology Technology:
(Date:11/16/2015)... 16, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced expansion of its TDDI product portfolio ... controller and display driver integration (TDDI) solutions designed ... new TDDI products add to the previously-announced ... (WQHD resolution), and TD4322 (FHD resolution) solutions. All ...
(Date:11/10/2015)... LONDON , Nov. 10, 2015 /PRNewswire/ ... segmented on the basis of product, type, ... segments included in this report are consumables, ... this report are safety biomarkers, efficacy biomarkers, ... in this report are diagnostics development, drug ...
(Date:11/2/2015)... Nov. 2, 2015  SRI International has been awarded ... preclinical development services to the National Cancer Institute (NCI) ... provide scientific expertise, modern testing and support facilities, and ... pharmacology and toxicology studies to evaluate potential cancer prevention ... The PREVENT Cancer Drug Development Program is an NCI-supported ...
Breaking Biology News(10 mins):